1. Home
  2. CC vs MESO Comparison

CC vs MESO Comparison

Compare CC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chemours Company (The)

CC

Chemours Company (The)

HOLD

Current Price

$15.66

Market Cap

2.5B

Sector

Industrials

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$17.43

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CC
MESO
Founded
2014
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.1B
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
CC
MESO
Price
$15.66
$17.43
Analyst Decision
Buy
Strong Buy
Analyst Count
9
1
Target Price
$20.11
N/A
AVG Volume (30 Days)
2.8M
180.5K
Earning Date
05-05-2026
02-26-2026
Dividend Yield
1.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,638,000,000.00
N/A
Revenue This Year
$6.15
$629.74
Revenue Next Year
$5.95
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
7.36
N/A
52 Week Low
$10.44
$12.66
52 Week High
$28.67
$21.50

Technical Indicators

Market Signals
Indicator
CC
MESO
Relative Strength Index (RSI) 45.66 59.57
Support Level $14.45 $17.69
Resistance Level $16.44 $19.53
Average True Range (ATR) 0.58 0.45
MACD 0.18 0.11
Stochastic Oscillator 71.82 80.20

Price Performance

Historical Comparison
CC
MESO

About CC Chemours Company (The)

The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: